Cold Chain Smart Solutions Conference

Fleming Europe19 - 21 January 2011, Barcelona, Spain
The Cold Chain Smart Solutions Conference is the perfect place to get up to speed with the latest regulations, technology and processes that are necessary to operate a cost-effective and compliant temperature controlled supply chain.

Due to greater temperature ranges and novel biotech drugs coming onto market the number of cold chain shipments by air, road and sea continue increasing. Temperature controlled and pharmaceutical shipping are widely expected to lead the recovery in terms of growth rates. Therefore the most immediate investment priorities of pharmaceutical, shipper, wholesaler companies and CMOs should include cold chain capabilities.

By attending you will have the chance to listen to conference presentations, panel discussions, specialist discussion forums, tailor-made streams about the burning topics of the industry - such as the most updated regulatory roadmap, quality systems and agreements, RF-enabled product visibility, electronic temperature monitoring, satellite tracking, "Last mile" issues, new market focus on Asia, shipping by ocean, cold chain packaging & shipping smart solutions: PCM, going green, active ULDs, battery-assisted passive RFID, etc.

In the frame of a highly interactive Post-Conference Workshop you will gain an insight into the newest real-life strategies how to mitigate the risks and optimize the cold chain costs efficaciously.

Furthermore, you will have excellent opportunities to network with temperature controlled supply chain stakeholders from:

  • Pharmaceutical, Biotech and Medical Device Manufacturers
  • Transportation Providers
  • Government Healthcare Agencies and Shippers
  • Freight forwarders
  • Packaging Partners
  • Wholesalers

As a comprehensive and one-of-its kind event, the Cold Chain Smart Solutions Conference will address the most urgent challenges of the global marketplace for the storage and distribution of temperature sensitive pharmaceuticals, biopharmaceuticals, vaccines, etc.

For further information and brochure request, please visit:
http://www.flemingeurope.com/life-science-conferences/europe/cold-chain-smart-solutions

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...